Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset ...

Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma ...

After getting slapped with a surprise refuse-to-file letter signed by former CBER Director Vinay Prasad, Moderna’s flu vaccine application will now go before the FDA’s Vaccine advisory committee. The ...

Hosted by Gator Bio at Timber + Tide from 1:00–6:00 pm PST, this event is designed for R&D Leaders, AI/ML platform teams, and ...

Biotech has been pulling off some remarkable science of late, while M&A and IPOs return to bolster the sector. But that doesn ...

By partnering with a UN-backed body, Roche has enabled companies to make the medicine for supply in 129 countries.

Lilly met analysts’ sky-high expectations with 28.3% weight loss over 80 weeks for the triple hormone receptor agonist ...

In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll be hearing ...

Kissei Pharmaceutical is reversing a recommendation related to Amgen-shared Tavneos that it made just a few days ago, now saying the rare disease drug can be given to new patients. Japan’s Ministry of ...

While both Beam Therapeutics and Wave Life Sciences touted notable biomarker benefits for their respective alpha-1 ...

UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study ...